English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The worldwide spread of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, particularly Escherichia coli, has significantly limited therapeutic options, especially for urinary tract infections. Although limited in their indications, fosfomycin and tigecycline are potential agents to treat infections due to ESBL-producing organisms. Although not routinely performed, susceptibility testing to both is necessary to ensure there is not an increase in resistance.

the canadian journal of infectious diseases and medical microbiology/canadian journal of infectious diseases and medical microbiology

Determination of Susceptibility to Fosfomycin and Tigecycline of Enterobacteriaceae, Particularly<i>Escherichia coli</i>Isolates, Producing Extended-Spectrum β-Lactamases from Multiple Regional Canadian Hospitals

Determination of Susceptibility to Fosfomycin and Tigecycline of Enterobacteriaceae, ParticularlyEscherichia coliIsolates, Producing Extended-Spectrum β-Lactamases from Multiple Regional Canadian Hospitals